The acquisition will strengthen Lupin’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
The new facility is scheduled to start operation in the first half of 2024
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Subscribe To Our Newsletter & Stay Updated
